

triptorelin (Triptodur)

Commercial Medical Benefit Drug Policy

Place of Service

Office Administration

Infusion Center Administration

Home Infusion

Drug Details

USP Category: HORMONAL AGENTS, SUPPRESSANT (ADRENAL OR PITUITARY)

Mechanism of Action: Gonadotropin releasing hormone (GnRH) agonist

HCPCS:

J3316:Injection, triptorelin, extended-release, 3.75 mg

How Supplied:

22.5 mg (extended-release injectable suspension)

Condition(s) listed in policy *(see coverage criteria for details)*

- Central Precocious Puberty
- Gender Dysphoria in Adolescents

Any condition not listed in this policy requires a review to confirm it is medically necessary. For conditions that have not been approved for intended use by the Food and Drug Administration (i.e., off-label use), the criteria outlined in the Health and Safety Code section 1367.21 must be met.

Special Instructions and Pertinent Information

Provider must submit documentation (such as office chart notes, lab results or other clinical information) to ensure the member has met all medical necessity requirements.

The member's specific benefit may impact drug coverage. Other utilization management processes, and/or legal restrictions may take precedence over the application of this clinical criteria.

For billing purposes, drugs must be submitted with the drug's assigned HCPCS code (as listed in the drug policy) and the corresponding NDC (national drug code). An unlisted, unspecified, or miscellaneous code should not be used if there is a specific code assigned to the drug.

The following condition(s) DO NOT require Prior Authorization/Preservice if ALL its parameters are met, otherwise Prior Authorization/Preservice is required.

Central Precocious Puberty

1. Documented diagnosis of central precocious puberty (neurogenic or idiopathic)

Covered Doses:

Up to 22.5 mg given as an intramuscular injection every 24 weeks

ICD-10:

E30.1

Gender Dysphoria in Adolescents

Covered Doses:

Up to 22.5 mg given as an intramuscular injection every 24 weeks

ICD-10:

F64.0, F64.1, F64.2, F64.9

References

1. AHFS. Available by subscription at <http://www.lexi.com>
2. DrugDex. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
3. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869-3903.
4. Triptodur (triptorelin) Prescribing Information. Azurity Pharmaceuticals Inc; Woburn, MA: 11/2023.
5. Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. *Int J Transgend Health*. 2022;23(Suppl 1): S1-S259. Published 2022 Sep 6. Available at: <https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644>.

Review History

Date of Last Annual Review: 3Q2025

Changes from previous policy version:

- No clinical change following annual review.

*Blue Shield of California Medication Policy to Determine Medical Necessity
Reviewed by P&T Committee*